Plasminogen activator inhibitor type 1 (PAI-1) is the main physiologic inhibitor of fibrinolysis. However, it is also involved in many physiological processes such as extracellular matrix (ECM) proteolysis and remodeling, cell adhesion, motility, and apoptosis, angiogenesis, etc. The aim of the study was to summarize current knowledge and gain insights into the mechanisms of PAI-1 action in the processes of stromal remodeling and diseases with considerable matrix pathologies (atherosclerosis, tissue fibrosis, cancer metastasis, pregnancy related complications, etc). As a component of an early cellular response to injury, PAI-1 reacts with membrane surface proteins and participates in the initiation of intracellular signaling, specifically cytoskeletal reorganization and motility. Complexity of ECM homeostasis resides in varying relation of the plasminogen system components and other matrix constituents. Inflammatory mediators (transforming growth factor-β and interferon-γ) and hormones (angiotensin II) are in the close interdependent relation with PAI-1. Also, special attention is devoted to the role of increased PAI-1 concentrations due to the common 4G/5G polymorphism. Some of the novel mechanisms of ECM modification consider PAI-1 dependent stabilization of urokinase mediated cell adhesion, control of the vascular endothelial cadherin trafficking and interaction with endothelial cells proteasome, its relation to matrix metalloproteinase 2 and osteopontin, and oxidative inhibition by myeloperoxidase. Targeting and/or alteration of PAI-1 functions might bring benefit to the future therapeutic approaches in diseases where ECM undergoes substantial remodeling.
INTRODUCTION
Plasminogen activator inhibitor type 1 (PAI-1) is a multifunctional protein involved in a number of physiologic processes, where it may exhibit its procoagulant, antiadhesive, proinflammatory, profibrotic or (anti)proteolytic effects. It is the main physiologic inhibitor of fibrinolysis; specifically tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA or urokinase). Through its effects on PAs, PAI-1 regulates plasmin and matrix metalloproteinases (MMP) activity and consequently tissue homeostasis [1] [2] [3] . However, the nature of its role in various biological processes is not always clear, and may comprise inhibition of fibrinolysis, extracellular matrix (ECM) proteolysis, cell adhesion, motility, and apoptosis, angiogenesis, etc. Beside the well-known influence of increased PAI-1 concentrations toward venous and arterial thrombosis, active PAI-1 involvement is determined in the pathogenesis of atherosclerosis, pulmonary fibrosis, cancer, and pregnancy related complications. Special attention has been devoted to its increased concentration due to the common 4G/5G polymorphism in the PAI-1 gene promoter region [1] [2] [3] [4] [5] [6] [7] . Various cytokines, as well as growth factors and hormones, can induce PAI-1 mRNA transcription. Some of these are interleukin-1 (IL-1) (ref. 8 ), tumor necrosis factor-α (TNF-α) (ref. 9 ), β-fibroblast growth factor (FGF) (ref. 10 ), transforming growth factor-β (TGF-β) (ref. 9 ), angiotensin II (AII) (ref. 5 ), thrombin 11 , etc. There are three conformational forms of PAI-1: active, latent, and substrate form. The active form spontaneously converts into a stable latent conformation. PAI-1 interaction with other proteins can stabilize its active conformation and prolong activity. Such is the association with vitronectin (VN), a protein that binds PAI-1 with high affinity in plasma, subendothelial matrix or platelets. VN is abundantly present in subendothelial matrix and may preserve PAI-1 activity in this compartment, making it physiologically relevant in ECM (ref. [12] [13] [14] . Extracellular matrix remodeling is controlled by the balance between proteases and their inhibitors. Plasminogen system is implicated in the processes of ECM degradation, where plasmin regulates pericellular proteolysis by the cleavage of MMPs, collagen, fibronectin, fibrin, proteoglycans. PAI-1 contributes to the both physiologic and pathophysiologic tissue/stromal remodeling, and thus takes essential part in wound healing process 1, 13, 14 .
The aim of the study was to summarize current knowledge and gain insights into the mechanisms of PAI-1 action in the processes of stromal remodeling and diseases with considerable matrix pathologies.
STROMAL REMODELING IN THE WOUND HEALING PROCESS
Wound healing is a dynamic process with distinct phases that require hemostasis, inflammation, tissue proliferation and differentiation. Beside well known antiproteolytic role of soluble PAI-1, the matrix-bound PAI-1 exerts important non-proteolytic actions in wound healing. In the initial stage, a significant increase of PAI-1 and u-PA were seen at the outermost edge of the wound, particularly in the newly deposited matrix as matrix-bound proteins. Concomitant increase of u-PA and u-PA receptor (u-PAR) is observed on migrating cells at their leading edge [15] [16] [17] . PAI-1 is shown to be prominent molecule of the early G0 to G1 transition transcriptome of human keratinocytes cell line, while the keratinocyte growth factor, secreted by the stromal fibroblasts during wound closure, is a powerful stimulator of PAI-1 expression 15 . The PAI-1 transcripts reached maximum at 2 h and were substantially decreasing at 4 h post-stimulation, which responds to mid G1 phase 18 . Urokinase initiated plasminogen activation is mainly required for pericellular proteolysis. Binding of u-PA to u-PAR at the cell surface activates plasminogen and enhances extracellular proteolysis 16 . At the same time, through the u-PA initiated conformational change of u-PAR, and associated adapter proteins, intracellular signaling is initiated, specifically -mechanical force transmission to the cytoskeleton. The u-PAR change makes it more attracted toward VN and integrins 17, 19, 20 and their interaction induce different molecular pathways (mitogen-activated protein kinase (MAPK), tyrosine kinases, Ras/extracellular-regulated signal kinase (ERK), etc), leading to cytoskeleton reorganization and cell migration. Thus, u-PA stimulates migration by uncovering a chemotactic epitope in u-PAR (ref. [21] [22] [23] ). PAI-1 enhances cellular motility through the both adhesion and deadhesion processes, depending on the local conditions. Normally, cells can anchor to the matrix's VN through their integrins or u-PAR molecules. When VN is present in sufficient amount, PAI-1 will bind it and thus inhibit cell adhesion by blocking u-PAR and integrin binding sites 17, 24 . The VN binding sites (somatomedin B domain) for PAI-1, u-PAR and integrin are clustered together and are overlapping, so these molecules may behave competitively. Additionally, PAI-1 has much higher affinity toward VN than u-PAR (ref. 19, 25 ). The local levels of VN and PAI-1 in ECM determine their promoting or inhibiting migration effect. Individually they have promigratory effect on vascular smooth muscle cells (SMC), but when together they form high-affinity complexes that annul promigratory effect of each other. Also, PAI-1 may convert VN to a self-associated multivalent form with enhanced cell/matrix binding properties (Fig. 1a) (ref. 22, 26 ). PAI-1 participates in cell detachment in a VN independent manner, which requires PAI-1 to u-PA binding and is associated with decrease in u-PAR-integrin complexes at the cell surface. Adequate concentrations of u-PA and PAI-1 lead to formation, internalization and inactivation of PAI-u-PA-u-PAR complex via LRP -{low-density lipoprotein (LDL) receptor-related protein (LRP)} dependent process 4, 27, 28 . When PAI-1 covalently attaches to u-PA in a solution, it blocks u-PA-induced cell migration (PAI-1-u-PA is inactive). The PAI-1-u-PA complex may bind with high affinity to u-PAR and cause its internalization. The PAI-1-u-PA becomes degraded intracellularly, while u-PAR is being recycled back to the surface. The complex internalization causes the cell to detach from ECM (Fig. 1b) (ref. 28, 29 ). If u-PAR internalization is blocked, PAI-1-u-PA complex is turned into a chemoattractant. This means that PAI-1 can detach cells from other ECM proteins without direct binding to them (fibronectin and type I collagen) (ref. 20 ). However, significantly fewer cells detach compared to VN because these proteins have multiple binding sites for integrins unlike VN (ref. 19 ). When bound to PA, PAI-1 losses affinity for VN, which could restore VN attachment site for VN receptor integrins at the cell surface. Meaning that local PA do not only initiate proteolysis and ECM degradation, but also helps to expose cell-attachment sites for the cell migration 30 . Additionally, PAI-1 can induce chemotaxis without u-PA involvement in vitro 29 . Active and inactive PAI-1 were shown to activate the JAK/STAT signaling system, with LRP being obligatory mediator, and thus stimulate cell migration. Non-complexed PAI-1 binds to LRP through the second site in PAI-1 molecule that is distinct from the one in PA-PAI-1 complexes (Fig. 1c) (ref. 31 ). Taken together, PAI-1 involvement in cell-matrix interaction can be partially explained through its different bonding affinity toward proteases and adhesive proteins, where it modulates the accessibility of protein's cell-attachment sites 30 . One of the newer studies report that u-PA and plasmin cleave VN. This process requires u-PA-u-PAR-VN binding and has negative impact on cell adhesion. PAI-1 was shown to counteract this function by stabilizing u-PAR mediated cell adhesion to VN (ref. 16 ). Several studies potentiate PAI-1 inhibitory effect on cell migration and its contribution to delay in wound closure. By blocking u-PA, PAI-1 hinders plasmin formation and ECM proteolysis. Second mechanism is disruption of cellular bond to VN (ref. 24, 32 ). Regarding this, significantly faster wound closure was determined in PAI-1 knockout (KO) mice, than wild-type (WT) (ref. 33 ). Also, higher fibrinolytic activity in PAI-1 (-/-) mice produced less fibrin and thus impaired cell migration/adhesion, because the amount of tissue fibrin affects migration. In contrast, PAI-1 (+/+) mice had higher fibrin levels and increased adhesion 3 .
ADVERSE VASCULAR REMODELING AND PAI-1
Participation in tissue remodeling gives PAI-1 a great importance in diseases where ECM undergoes change or damage (cardiovascular diseases, cancer, brain injury, obesity, bone remodeling). In regard, PAI-1 is involved in the injured vessel repair and regulation of intima formation 1, 4, 12, 34 . Neointima hyperplasia refers to the proliferation and migration of vascular SMCs in the intima that results in its thickening. Endothelial denudation is the primary injury event which triggers an inflammatory reaction, hemostasis, and fibrinolysis. Endothelial cells (EC) produce growth factors necessary for SMC proliferation (FGF, PDGF, TGF-β), while leukocytes release cytokines, among which NF-κB, TNF-α and IL-1β are pivotal for neointima formation 5, 26 . In reply, TNF-α stimulates ECs to form microparticles on their surface which provide an area for u-PA/u-PAR mediated plasmin formation, supporting endothelial involvement in proteolytic activities (angiogenesis) necessary for SMC migration 35 . Animal studies provided opposite results on neointima formation depending on the PAI-1 genotype, type of vascular injury, phases of wound healing, part of the vasculature, and presence of other clotting factors 4, 26, 36 . Upon vascular injury PAI-1 levels correlate with neointima formation while thrombus formation and fibrin deposition further modulate its anti-fibrinolytic effect. Thrombin, PAI-1, and VN were found co-localized at the site of vascular injury and atherosclerotic lesion. In association with VN, PAI-1 is an efficient local inhibitor of thrombin, in vitro and in vivo, that can block thrombin induced SMC proliferation [36] [37] [38] [39] . Deposited fibrin serves as a chemotactic agent that promotes cell migration to the injury site. VN mediated PAI-1 binding to fibrin clots is dependent on direct VNfibrin interaction 3, 40 . The presence or absence of thrombus and fibrin on neointima led to contradicting observations on PAI-1 effects in animal model studies 36, 38, 41 . In contrast to ferric chloride, mechanical and electrical injuries of mouse vessels are not associated with significant thrombus formation, thus the cell migration occurs in the absence of fibrin. High PAI-1 levels could impede neointima formation through the inhibition of u-PA mediated proteolysis, which would stabilize ECM; or by binding to VN and prevention of u-PAR-integrin mediated cell attachment 37 . However, severe electric injury causes extensive fibrin deposition in both WT and transgenic mice overexpressing PAI-1. The transgenic mice had significantly reduced in situ fibrinolytic activity but comparable intima/ media ratios, and SMC distribution pattern. Increased PAI-1 levels did not affect neointima formation at the injury with extensive fibrin deposition 41 . Hasenstab and colleagues 42 found that during carotid artery injury by angioplasty, expression of two proteins were changed, PAI-1 and tissue inhibitor of MMP-2. The expression was primarily increased in medial SMCs, confirming the importance of proteolytic activity for SMC migration in response to injury. In vitro PAI-1 overexpression increased mural thrombus accumulation in early phase (1 week) after injury 34 , but reduced intimal thickening and neointimal area (30% at 1 week), without altering matrix accumulation. Local PAI-1 overproduction in injured vessel wall decrease plasmin production and consequently MMPs activation leading to reduced remodeling 2 . On the other hand, the same experiment showed PAI-1 overexpression accelerated re-endothelization of the injured arteries 34 . Promotor of the PAI-1 gene contains regulatory elements including TGF-β response site 43 . TGF-β1 stimulates PAI-1 expression in the artery wall and promotes neointima growth through the PAI-1 dependent pathways. TGF-β1 overexpressing PAI-1 (-/-) mice did not show increased intimal growth, matrix accumulation, cell migration or proliferation. Also, they secreted 6-to 10-fold more TGF-β1 than WT mice, suggesting PAI-1 was a negative regulator of TGF-β1 and a mediator of intimal growth 44 . Plasmin exerts proteolytic activity on TGF-β and is required for its conversion from latent to active form. Decreased plasmin production would decrease TGF-β activation and thus increase SMC proliferation 1, 2 . Another mechanism by which PAI-1 may modulate vascular wall is cell apoptosis. Elevated intracellular PAI-1 levels were associated with induced apoptosis. Its direct interaction with α-3 subunit of proteasome in ECs prevented degradation of p53 and inhibitor of kappa B (IκBa) (ref. 45 ). Also, atherosclerotic vessel apoptotic cells lining correlated with components of plasminogen activation system and the PAI-1 inhibition of VN dependent cell adhesion. PAI-1 induced double increase in apoptosis of umbilical-vein ECs and vascular SMCs adherent to VN in vitro, independently of u-PA (ref. 41 ).
PAI-1 IN ATHEROSCLEROSIS AND MYOCARDIAL INFARCTION
Increased PAI-1 blood levels are shown to be an independent risk factor for coronary artery disease, myocardial infarction (MI), and cerebrovascular events, as well as atherosclerosis progression and complications, such as plaque rupture or restenosis 4, 46 . Locally elevated PAI-1 levels are observed in atherogenic lesions of coronary arteries 47 and advanced atherosclerotic plaques 34 . Mechanisms by which elevated plasma PAI-1 may affect atherosclerosis is the inhibition of fibrin clearance from plaques (ineffective fibrinolysis) and possible change in cellular content, especially SMC (ref. [1] [2] [3] [4] ). PAI-1 gene expression was found upregulated in macrophages and SMCs in human atherosclerotic lesions 37, 47 , while oxidized LDL upregulated PAI-1 expression in ECs and SMCs in vitro 37 . Although fibrin formation and deposition participate in plaque growth, it is the primary event in the healing of damaged plaques. Also, we must consider concurrent increase in tissue factor expression 48 and PAs levels 47 within the plaque. A meta-analysis in 2010 determined no association of PAI-1 4G/4G polymorphism with MI and coronary artery disease, but only a marginal association with atherosclerosis 6 . Inflammation and increased C-reactive protein (CRP) levels contribute to fibrin deposition and are risk factors for vein graft thrombosis after bypass surgery. Similarly to IL-1 and TNF-α, CRP is shown to induce PAI-1 mRNA in ECs in vitro and in vivo, together with tissue factor 2 . At least part of the locally increased PAI-1 in the vascular wall, in the early stages after vein graft surgery, is proposed to originate from plasma PAI-1 transition due to the loss of ECs barrier 48, 49 . Additionally, since AII stimulates the expression of PAI-1 gene, the conditions with renin-angiotensin-aldosterone (RAA) system activation are expected to have PAI-1 levels increased. Modulation of PAI-1 levels by AII depends upon timing, location, and its concentrations, thus PAI can be related to both vascular injury and recovery 5 . Besides its causal role on MI development via coronary thrombosis, the plasminogen system influences tissue remodeling after MI. Various cardiac cells (cardiomyocytes, ECs, fibroblasts, mast cells) produce PAI-1 after MI (ref. [49] [50] [51] ), which could further affect progression of left ventricle (LV) dysfunction. The increased PAI-1 expression may contribute to interstitial and perivascular cardiac fibrosis, demonstrated by ECM accumulation, through the potential PAI-1 mediated inactivation of PAs and MMPs (ref. 51, 52 ). Askari and colleagues 52 observed significant influence of myeloperoxidase (MPO) and PAI-1 in LV response immediately after acute MI. The MPO generated oxidants significantly chlorinated and inhibited PAI-1, which lead to increased u-PA and plasmin activity. Beside decreased leukocyte entry into the infarcted zone, MPO (-/-) mice displayed decreased oxidative inactivation of PAI-1 and plasmin activity. MPO null mice demonstrated preservation of LV function, while PAI-1 null mice had accelerated myocardial rupture. Cardiac rupture in acute MI was more frequent in t-PA (-/-), u-PAR (-/-), and PAI-1 (-/-) mice, while u-PA (-/-), MPO (-/-), and MMP-9 (-/-) were protected. However, u-PA (-/-) and plasminogen (-/-) mice had impaired scar formation and revascularization 52, 53 . Plasminogen (-/-) mice had deprived inflammatory cells activation and infiltration into the infarcted myocardium, hindered necrosis removal, delayed healing, and abolished fibrous tissue formation, thus their infarcted myocardium remained thicker than in WT animals 53, 54 . Significant coronary perivascular fibrosis developed in operated (artery ligation) mice compared to "sham" and PAI-1 deficient mice. Important difference, that might significantly influence the results, is a different expression of cytokines TGF-β and TNF-α. Surgically treated mice had regional increase of these cytokines compared to other animals. Interestingly, plasma PAI-1 levels were increased in post-MI mice, but there was no upregulation of PAI-1 mRNA in other organs suggesting that cardiac sources contributed to the elevated plasma PAI-1 levels 51 .
TISSUE FIBROSIS AND PAI-1
PAI-1 involvement in fibrotic diseases is well documented 5, 51, 55 . Tissue fibrosis is often a consequence of deregulated wound healing, where hyperactive fibroblasts produce excessive accumulation of ECM. Prolonged inflammation and fibrin accumulation contribute to the process, where inflammation triggers profibrotic cytokine signaling (such as TGF-β) that activates fibroblasts and stimulate transformation of endothelial, epithelial or hepatic stellate cells into myofibroblasts. The PAI-1 anti-fibrinolytic activity gives advantage to the fibrin accumulation, further modulating inflammatory and collagenproducing cell migration 3, 56 . Physiologically, elevated PAI-1 expression in the initial phase expedite wound healing by protecting ECM proteins. PAI-1 blocks u-PA/t-PA activation and consequently plasminogen, MMPs, and TGF-β activation, thus retarding ECM turnover 3, 15, 16, 57 . However, pathologically prolonged low ECM degradation leads to the excessive collagen accumulation. Numerous studies show the protective effects of PAI-1 deficiency toward induced fibrosis of most organs, except for skin and spontaneous age-related cardiac fibrosis in mice 5, 33, 50, 51, 55 . Interestingly, spontaneous age-related cardiac fibrosis in PAI-1 null mice is not associated with significant fibrosis after MI. Macrophage specific u-PA overexpression in these animals significantly contributes to the process 58 . Moreover, PAI-1 maintains endothelial integrity and permeability by controlling the vascular endothelial cadherin trafficking. Disruption of the cadherin junctions leads to increased endothelial permeability 59 . Microvascular leakage in PAI-1 (-/-) mice was shown to contribute to cardiac fibrosis through enhanced local inflammation. Fibrosis with extensive interstitial collagen accumulation develops spontaneously and progressively with aging. Expression of MMP-2, MMP-9, u-PA, and tissue inhibitor of MMP-2 were elevated in PAI-1 (-/-) mice, while increased TGF-β levels and signaling led to increased endothelial to mesenchymal transition. Due to all these facts PAI-1 is suggested to have a cardioprotective role concerning fibrosis 3, 55 .
Pulmonary fibrosis involves alveolar epithelial injury.
In an alveolar epithelial cell wounding model u-PA deficiency negatively affected wound closure, while PAI-1 deficiency significantly enhanced healing efficiency. The negative effect of PAI-1 to alveolar repair was explained by its binding to VN, because enhanced alveolar epithelial cell motility is determined by VN availability. VN accumulates at the sites of exudates pulling along PAI-1 at the sites of injury, where it can initially inhibit fibrin degradation and later matrix turnover 32, 50, 60 . Environmental pollutants (nickel, silica) may exacerbate lung injury as they are capable of inducing PAI-1 expression through the activity of ERK1/2 MAPK pathways. Additionally, alveolar macrophages can generate plasmin, suggesting potential activation of TGF-β after injury 58, 61 . PAI-1 deficiency is reported to protect the lungs from excessive fibrin accumulation and fibrosis. This effect may partly be explained through the enhanced fibrinolytic activity. Secondly, TGF-β failed to induce epithelial to mesenchymal transition in these animals 3 . One recent study reported an additional mechanism that protects PAI-1 deficient mice from lung fibrosis. That is an elevated production of prostaglandin E2 through the plasmin/hepatocyte growth factor (HGF)/COX-2 axis, an anti-fibrotic mediator associated with increased plasmin generation 62 . PAI-1 expression and levels had been found increased in many fibrotic renal diseases characterized by ECM accumulation and experimental models of glomerulosclerosis 3, 63, 64 . Elevated TGF-β and RAA system components in renal diseases pathogenesis contribute to the enhanced PAI-1 expression 65 . The results of experimental studies on PAI-1 role in renal fibrosis are often contradictory, mainly due to different models used, especially relating to the aggressiveness and speed at which the kidney injury develops.
In rapidly developing kidney disease, the inflammatory reaction is dominant and PAI-1 effect is directed toward macrophage migration and TGF-β1 activation 65 . PAI-1 activation occurs in the early phase of glomerular injury, which is associated with cell migration. In the antibodies induced glomerulonephritis the inhibition of endogenous PAI-1 reduced inflammatory cell infiltration. The number of monocytes/macrophages per glomerular cross section was reduced, leading consequently to reduction of glomerulosclerosis 60 . The PAI-1 (-/-) mice had significantly lower number of interstitial macrophages and myofibroblasts than WT at day 3 after the unilateral ureteral obstruction injury. Additionally, decreased cellularity was associated with reduced TGF-β and procollagens expression 66 . PAI-1 and TGF-β seem to be in intricate relation influenced by tissue cellularity, especially inflammatory cell infiltration, and by different cytokines and hormones present. TGF-β 1 stimulates collagen deposition in both glomerular and interstitial ECM, and PAI-1 deficiency hinders this effect. In the study of a s lowly progressive TGF-β1-induced kidney injury, which lacks a major inflammatory component, TGF-β1 overexpression stimulated PAI-1 mRNA and interstitial collagen deposition, while PAI-1 null mice showed reduced collagen expression and accumulation. The beneficial effect of PAI-1 deficiency was not due to immunomodulation or fibrinolysis, but to the impeded ECM synthesis. A proposed mechanism is PAI-1 interference with the integrin to VN binding and/or compensatory inc rease in other PAs inhibitors 65 . PAI-1 deficient mice were protected against interstitial fibrosis after 12 weeks aldosterone administration 57 . AII causes dual stimulation of PAI-1 transcription: A rapid one -directed to PAI-1 gene up-regulation in the early phase, and a later one that is indirect and mediated by TGF-β. AII up-regulates TGF-β gene and thus stimulates ECM synthesis, so that prolonged effect of AII on PAI-1 protein synthesis depends on concomitant TGF-β activity 57, 60 . Several plasmin independent pathways are discussed for decreased total collagen content in the aldosterone treated PAI-1 null mice with ECM degradation. Increased MMP-2 activity is one of the mechanisms, as it is higher in PAI-1 null mice than WT. Nevertheless, decreased MMPs activity in diabetic PAI null mice argues that ECM degradation is the major cause of attenuated fibrosis 57, 60, 64 . Another suggestion is the action of osteopontin, a proinflammatory mediator and adhesin, which is induced by aldosterone. It can stimulate vascular SMCs proliferation and migration, and contributes to macrophages recruitment. Its expression was found significantly lower in PAI-1 (-/-) mice. Physiologically, osteopontin is produced when cell's integrins bind to a collagen or fibronectin, thus PAI-1 deficiency-mediated ECM degradation may attenuate this reaction 60, 67 .
The PAI-1 role in liver fibrogenesis was demonstrated in a rat model where antifibrotic drug (interferon (IFN)-α 2a) led to reduced collagen and PAI-1 production and subsequently amelioration of the cirrhosis 68 . Abdominal adhesions formation after hepatectomy is influenced by natural killer (NK) cells and their production of IFN-γ, which seems to be the key regulator of this process through the balance of PAI-1/t-PA levels. That is, marked increase of PAI-1 and decrease of t-PA expression. The HGF (anti-fibrotic agent) was shown to inhibit adhesion formation as it reduces IFN-γ and PAI-1 levels, but increases t-PA (ref. 69 ).
THE ROLE OF PAI-1 IN EMBRYO IMPLANTATION AND PLACENTATION
The plasminogen system is believed to regulate maternal tissue remodeling during embryonal implantation, through successful trophoblast invasion and uteroplacental vasculature adaptation. Different distribution and time coordination of PAs and their inhibitors (PAI-1 and PAI-2) have important fibrinolytic roles in the early stages of placenta formation as well as its separation from maternal tissue during birth 7, 70 . Prostaglandins regulate trophoblast invasion in early pregnancy by stimulation of PAI-1 and inhibition of MMPs expression in stromal cells 71 . Likewise, glucocorticoids have an important effect on trophoblast growth and ECM degradation during invasion through the increase of PAs with fibrinolysis which is necessary for efficient vascularization. Dexamethasone was observed to significantly enhance TGF-β dependent PAI-1 expression in cytotrophoblasts in vitro, unlike estradiol, prostaglandins or testosterone. If elevated, PAI-1 could counteract fibrinolysis and potentially impair placental blood exchange leading to pre-eclampsia (PE) and intrauterine growth retardation (IUGR). These pregnancies were accompanied by excessive ThPAI-1 levels in placenta together with abnormal fibrin deposition. Among others, glucocorticoid receptor and RAA signaling pathways are found significantly involved in preterm PE placenta tissues 70, 72 . Uterine NK cells produce several cytokines and growth factors that affect trophoblast invasion. These cytokines (TNF-α, TGF-β, IFN-γ) were shown to inhibit extravillous cytotrophoblast (EVT) invasion in vitro. Mechanisms of action included down-regulation of MMPs and u-PA, upregulation of PAI-1, and increased apoptosis 71, 73 . TNF-α increases apoptosis of villous cytotrophoblast cells and stimulates expression of PAI-1, u-PA and MMP-9 by EVT (ref. 74 ). Increased PAI-1 levels are speculated to cause impaired proteolysis and promote fibrin deposition thus limiting trophoblast advancement which may favor unexplained early recurrent miscarriage 7 . Increased fibrin deposition with low trophoblast invasion and thrombolysis results in microthrombosis with further hypoxia and nutrition depletion. Matching changes were found in placental vascular bed biopsies, showing defective deep placentation with restricted remodeling and obstructions in the myometrial segment of the spiral arteries 75 . Homozygosity of PAI-1 4G/5G, or compound carrier status with FXIII Val34Leu mutation, significantly increased the overall relative risk for early recurrent pregnancy loss 7 . Several clinical studies associated altered PAI-1 functionality to development of pregnancy related complications, specifically PE and IUGR. PAI-1 blood levels were found increased in these patients, along with high placental expression, suggesting the placenta is the primary source for its increased serum concentrations. Villous syncytiotrophoblast was found responsible for this enhanced PAI-1 expression and reduced perivillous fibrinolysis in patients. In contrast, PAI-2 levels were reduced in placenta 70, 76 . Venous umbilical PAI-1 was significantly increased (~10-fold) in hypoxemic placental insufficiency compared to controls. These levels had a positive predictive ratio of 6.7, suggesting that circulating PAI-1 levels can be used as an indicator of placental insufficiency 77 . PAI-1 umbilical blood levels were positively associated with plasma's angiogenic potency (in vitro) demonstrating the role of PAI-1 in angiogenic regulation in growth restricted pregnancies. The proangiogenic activity of PAI-1 is thought to be related to the composition of stable ECM and therefore cell migration and proliferation 78 .
THE ROLE OF PAI-1 IN CANCER METASTASIS
As a number of studies demonstrate, u-PA and PAI-1 have strong prognostic and predictive value as cancer biomarkers 19, 28, 78, 79 . Their levels in primary tumor breast tissue extracts can distinguish patients risk of disease recurrence. In the long-term follow-up study u-PA and PAI-1 levels strongly indicated an aggressive course of lymph node-negative breast cancer, independent of the HER2 status. Their low levels in primary tumors were associated with a very good prognosis, in contrast to high values that were connected to increased risk of relapse, despite negative nodes. Therefore, the American Society of Clinical Oncology has recommended their assessment for adjuvant chemotherapy use in node-negative breast cancer patients 79, 80 . ECM degradation is one of the crucial events in cancer metastasis. Proteolytic enzymes (MMPs and plasminogen system) secreted by tumor and inflammatory cells enable this process 81 . Cancer cells can use the u-PA system in multiple ways. By overexpressing pro-u-PA, u-PAR and plasminogen receptors, malignant cells can generate plasmin de novo on the membrane surface or in close vicinity, aiming for suitable microenvironment for its progression. By producing specific inhibitors (PAI-1 and PAI-2) they also regulate PAs (ref. 11, 28, 35 ). Myoepithelial cells of ductal carcinoma in situ (DCIS) express components of plasminogen system and their u-PAR to VN bond helps in cell-matrix interaction, thus controlling cell adhesion or detachment. It is speculated that PAI-1 could cause an interruption of myoepithelial cell layer and the loss of anti-invasive DCIS properties 82 . However, u-PAR expression was observed in invasive duc-tal carcinoma infiltration, but not in DICS. While u-PA and PAI-1 were detected in both types, with stronger expression in invasive carcinoma. PAI-1 anti-proteolytic activity at the initial stage, when u-PAR is not expressed, may prevent cancer spreading, however at later stages when the expression of other u-PA components is established, different mechanisms are employed. Therefore, direct cancer proteolysis of ECM can be counteracted by PAI-1, but increased PAI-1 may also influence cell detachment 28 . PAI-1 shows chemokine-like activity as it increases filopodia formation and cell migration of invasive cell lines. u-PAR and u-PA were found co-localized with chemokine receptors at the leading edge of fast-migrating cells, whereas PAI-1 was adsorbed on ECM and when in high concentrations it promoted migration 28, 83 . Another mechanism of the most aggressive cancer cells involves employment of matrix-bound PAI-1 for mesenchymalamoeboid transition and metastatic escape. The new mechanism involves amoeboid migration and cell blebbing, where PAI-1 maintains these processes by localizing phosphoinositide-dependent kinase-1 and ROCK1 (Rhoassociated Coil-containing Protein Kinase 1) at the cell membrane and mediating activation of RhoA/ROCK1/ MLC-P (Myosin Light Chain) pathway 21 . This aside, lack of plasminogen was shown to reduce angiogenesis 35, 53 . In contrast, PAI-1 promoted tumor angiogenesis, but not through the facilitated ECs migration via ECM interaction. The emphasis is on proteolysis as the salient mechanism of tumor angiogenesis. However, the process requires tumor induction of host microvessels and must be balanced by additional factors that provide vessel stabilization and maturation 78 .
CONCLUSION
The function of PAI-1 is not restricted to the inhibition of intravascular fibrinolysis but is also important in a vast number of tissue remodeling processes that involve cell motility and their interactions with ECM. PAI-1 is a component of early cellular response to injury and by reacting with membrane surface proteins it participates in cell adhesion and initiation of intracellular signaling, specifically cytoskeletal reorganization. The complexity of ECM remodeling resides in varying relation of the plasminogen system components and other matrix constituents. The mechanisms of PAI-1 action are affected by inflammatory mediators and cytokines, among which TGF-β and INF-γ are in interdependent relation with PAI-1. Targeting and/ or alteration of PAI-1 functions might provide benefit to future therapeutic approaches in diseases where ECM undergoes substantial remodeling.
Search strategy and selection criteria
Our research strategy was aimed at evaluating studies on the role of plasminogen activator inhibitor 1 regarding molecular mechanisms in stromal remodeling, in order to comprehend and summarize the current knowledge of PAI-1 involvement in this processes. Scientific articles 
